Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

7.3%

4 terminated/withdrawn out of 55 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

27%

15 trials in Phase 3/4

Results Transparency

90%

18 of 20 completed trials have results

Key Signals

20 recruiting18 with results

Enrollment Performance

Analytics

Phase 2

19(37.3%)

Phase 3

9(17.6%)

Phase 1

7(13.7%)

Early Phase 1

6(11.8%)

Phase 4

6(11.8%)

N/A

4(7.8%)

51Total

Phase 2(19)

Phase 3(9)

Phase 1(7)

Early Phase 1(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials

NCT07455903Phase 2Recruiting

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Role: collaborator

NCT07733908Phase 2Not Yet Recruiting

Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Role: collaborator

NCT07702292Phase 2Recruiting

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: lead

NCT06604442Phase 4Completed

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Role: lead

NCT04175431Phase 2Recruiting

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Role: collaborator

NCT05722925Phase 4Active Not Recruiting

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Role: collaborator

NCT04018053Early Phase 1Completed

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Role: collaborator

NCT07432633Phase 1Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: lead

NCT06159335Phase 3Recruiting

18F-FLUC PET/MR in Patients With Brain Mets

Role: collaborator

NCT07569926Phase 4Not Yet Recruiting

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Role: lead

NCT06015295Not ApplicableActive Not Recruiting

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

Role: collaborator

NCT07393867Phase 2Recruiting

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Role: collaborator

NCT06048094Phase 1Recruiting

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Role: collaborator

NCT06862856Recruiting

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Role: collaborator

NCT07568756Phase 2Not Yet Recruiting

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Role: collaborator

NCT05555550Early Phase 1Recruiting

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Role: collaborator

NCT04689048Phase 1Recruiting

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Role: collaborator

NCT05678322Phase 3Active Not Recruiting

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Role: collaborator

NCT07011342Not ApplicableRecruiting

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Role: collaborator

NCT07164027Early Phase 1Recruiting

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Role: collaborator